Please login to the form below

Not currently logged in
Email:
Password:

Sanofi’s US pharma head joins Synta as CEO

Anne Whitaker also has experience at GSK
synta-anne-whitaker

Synta Pharmaceuticals has named the former head of Sanofi's pharma operations in the US and Canada as its new CEO.

Anne Whitaker served as president, North America pharmaceuticals, at Sanofi since September 2011 overseeing all pharma and consumer healthcare operations within the region. She also served as a member of Sanofi's global leadership team, global commercial operations committee and US regional management committee.

She now leads an emerging US-based biopharma focused on the development of small molecule drugs to treat patients with severe medical conditions, including cancer and chronic inflammatory diseases.

“Synta presents an exciting opportunity defined by a late stage product, ganetespib, that has shown promising activity in multiple indications and a pre-clinical programme, HDC, that has significant potential to generate new drug candidates,” said Whitaker.

Prior to joining Sanofi in 2011, Whitaker spent nearly two decades at GlaxoSmithKline (GSK), progressing through the ranks to eventually hold a senior VP role. She began her career at Delta Communications before joining the Upjohn Company in 1991 as a metabolic disease specialist.

14th August 2014

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics